1. Home
  2. HYFM vs PFSA Comparison

HYFM vs PFSA Comparison

Compare HYFM & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hydrofarm Holdings Group Inc.

HYFM

Hydrofarm Holdings Group Inc.

HOLD

Current Price

$1.98

Market Cap

11.2M

Sector

Industrials

ML Signal

HOLD

PFSA

Profusa Inc.

N/A

Current Price

$0.12

Market Cap

11.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYFM
PFSA
Founded
1977
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
11.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
HYFM
PFSA
Price
$1.98
$0.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
97.1K
10.1M
Earning Date
11-12-2025
11-19-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$146,443,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$37.86
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
122.22
52 Week Low
$1.50
$0.10
52 Week High
$7.50
$12.76

Technical Indicators

Market Signals
Indicator
HYFM
PFSA
Relative Strength Index (RSI) 47.39 N/A
Support Level $1.51 N/A
Resistance Level $2.74 N/A
Average True Range (ATR) 0.31 0.00
MACD 0.06 0.00
Stochastic Oscillator 32.11 0.00

Price Performance

Historical Comparison
HYFM
PFSA

About HYFM Hydrofarm Holdings Group Inc.

Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.

About PFSA Profusa Inc.

Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.

Share on Social Networks: